Approximately 14 million Americans are addicted to drugs and alcohol.The federal government estimates that these addicts cost the U.S. economy $300 billion in medical expenses and lost productivity.Despite the enormous potential market, many biotech companies have shied away from funding research and development (R&D) initiatives to find a cure for drug and alcohol addiction.Your firm - Drug Abuse Sciences (DAS) - is a notable exception.It has spent $225 million to date working on a cure, but is now at a crossroads. It can either abandon its program or invest another $50 million today.Unfortunately, the firm's opportunity cost of funds is 6 percent and it will take another five years before final approval from the Federal Drug Administration is achieved and the product is actually sold. Expected (year-end) profits from selling the drug are presented in the accompanying table.

Year 1 $0

Year 2 $0

Year 3 $0

Year 4 $0

Year 5 $11,300,000

Year 6 $15,900,000

Year 7 $17,400,000

year 8 $19,100,000

year 9 $22,300,000

What is the net present value of the project?

Instruction:Enter your response rounded to the nearest penny (two decimal places). Use a negative sign (-) where appropriate.

$

Should DAS continue with its plan to bring the drug to market, or should it abandon the project?

Abandon or Continue